AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 511419
Drug: Solvent injection
RxNorm normalized name: solvent yellow 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent injection (control)
Trial: 24156306
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (12 mmol/l citrate, HCO3- 32 mmol/l replacement fluid)
Trial: 24156306
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (18 mmol/l citrate with phosphate-containing dialysate/replacement fluid, HCO3- 30 mmol/l, Phosphate 1.2)
Trial: 21335007
Drug: PegIFN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN therapy
Trial: 19542983
Drug: Pregabalin 300-450
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300-450 mg/day
Trial: 19352198
Drug: Benzodiazepines (alprazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines (alprazolam 1.5 mg/day; lorazepam 6 mg/day)
Trial: 16723311
Drug: Formulation 1
RxNorm normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 1 containing 250 mg vitamin C
Trial: 16723311
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2 containing 250 mg vitamin C
Trial: 16723311
Drug: Formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 3 containing 250 mg vitamin C
Trial: 9315597
Drug: Low-dose pravastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pravastatin combined with low-dose cholestyramine
Trial: 9315597
Drug: High-dose pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pravastatin monotherapy
Trial: 15015647
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (HCC)
Trial: 29579195
Drug: MST3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST3 (3 rounds of mass screening and treatment)
Trial: 29579195
Drug: MST2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST2 (2 rounds of mass screening and treatment)
Trial: 29579195
Drug: MST0 (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST0 (no mass screening and treatment)
Trial: 27076772
Drug: Active care
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active care (6 mo colonoscopy and drug intensification for endoscopic recurrence)
Trial: 27076772
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (drug therapy without early endoscopy)
Trial: 25420889
Drug: Lansoprazole (LS)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LS) 30mg once daily for 4 weeks
Trial: 25420889
Drug: Lansoprazole (LS)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LS) 30mg once daily for 1 week followed by Ecabet Sodium (ES) 1500mg twice daily for 3 weeks
Trial: 20723034
Drug: Terutroban 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 1 mg day(-1)
Trial: 20723034
Drug: Terutroban 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 2.5 mg day(-1)
Trial: 20723034
Drug: Terutroban 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 5 mg day(-1)
Trial: 20723034
Drug: Terutroban 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 10 mg day(-1)
Trial: 20723034
Drug: Terutroban 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 30 mg day(-1)
Trial: 16689755
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg day(-1)
Trial: 15892271
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI) plus chemotherapy (CT)
Trial: 15892271
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) only
Trial: 12322846
Drug: Enaril 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enaril 5 mg tablets
Trial: 10426610
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (200 microg tablet for at least four hours)
Trial: 10426610
Drug: Vaginal gemeprost
RxNorm normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gemeprost (1.0 mg vaginal suppository for at least three hours)
Trial: 7897139
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy or implantable cardioverter‐defibrillator therapy
Trial: 30888737
Drug: CNTX‐4975 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTX‐4975 0.5 mg
Trial: 30888737
Drug: CNTX‐4975 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTX‐4975 1.0 mg
Trial: 28984010
Drug: rhFVIIa 25
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFVIIa 25 μg/kg
Trial: 28984010
Drug: rhFVIIa 75
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFVIIa 75 μg/kg
Trial: 28984010
Drug: rhFVIIa 225
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFVIIa 225 μg/kg
Trial: 28984010
Drug: rhFVIIa (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFVIIa (all doses)
Trial: 21472665
Drug: Control (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (optimal diet therapy, sulfonylurea and/or insulin)
Trial: 11273919
Drug: Fentanyl continuous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl continuous infusion (Group 2)
Trial: 11273919
Drug: Fentanyl-midazolam infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl-midazolam infusion (Group 3)
Trial: 9298429
Drug: Primarily noradrenergic
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primarily noradrenergic reuptake inhibitor (desipramine)
Trial: 9298429
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) (sertraline or paroxetine)
Trial: 9298429
Drug: Combined serotonin
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined serotonin and norepinephrine reuptake inhibitor (SNRI) (venlafaxine)
Trial: 8420442
Drug: Fosinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10 mg initial oral daily dose, then 20 mg once a day during open-label phase)
Trial: 24819566
Drug: Darbepoetin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbepoetin (10 μg/kg, 1×/week subcutaneously)
Trial: 24819566
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham dosing 3×/week)
Trial: 12924802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (acetaminophen, NSAIDs, and education)
Trial: 10640258
Drug: Zolmitriptan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (2.5 mg or 5 mg)
Trial: 10640258
Drug: Zolmitriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (5 mg)
Trial: 2669067
Drug: APD (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD (300 mg/day orally)
Trial: 71972
Drug: Flurbiprofen 150
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 150 mg daily
Trial: 71972
Drug: Flurbiprofen 150
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 150 mg daily plus 3 g aspirin daily
Trial: 29200944
Drug: Therapeutic cervical
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cervical medial branch blocks (with or without steroids)
Trial: 24121097
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment for insomnia with weekly email support
Trial: 24121097
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment for insomnia without support
Trial: 12950862
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil
Trial: 19812445
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg maraviroc
Trial: 12730746
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg risedronate
Trial: 12730746
Drug: Risedronate (1-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (1-5 mg doses)
Trial: 12730746
Drug: Risedronate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (up to 5 mg)
Trial: 2680843
Drug: RS 86
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS 86 (cholinergic agent)
Trial: 25331469
Drug: Ropivacaine local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine local infiltration (0.5% ropivacaine, 40 ml, n = 22)
Trial: 25331469
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride local infiltration (0.9% sodium chloride, 40 ml, n = 20)
Trial: 25331469
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no analgesic, n = 19)
Trial: 10343261
Drug: Intravenous triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triiodothyronine (0.4 microgram/kg bolus plus 0.1 microgram/kg infusion over 6 hours, n = 81)
Trial: 10343261
Drug: Intravenous triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triiodothyronine
Trial: 7594443
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg capsule)
Trial: 7594443
Drug: Dihydralazine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (intravenous infusion at a rate of 1-3 mg/h)
Trial: 28586878
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of at least 500 mg/d of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFAs)
Trial: 25698759
Drug: Alcohol intoxication
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol intoxication (0.75 g/kg)
Trial: 23345623
Drug: FIR therapy
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIR therapy (40 min, three times weekly for one year)
Trial: 23345623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FIR therapy)
Trial: 23345623
Drug: FIR therapy
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIR therapy
Trial: 18663500
Drug: moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg i.v. once daily
Trial: 18663500
Drug: amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulanic acid 2.2 g i.v. three times daily
Trial: 18663500
Drug: moxifloxacin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin and amoxicillin/clavulanic acid
Trial: 17227570
Drug: 15 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg/mL IDN-6556 (Organ storage/flush)
Trial: 17227570
Drug: 5 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Trial: 17227570
Drug: 15 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Trial: 10863139
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg single dose (Study A)
Trial: 10863139
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg single dose (Study B)
Trial: 7818840
Drug: Captopril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (angiotensin-converting enzyme inhibitor)
Trial: 29421001
Drug: Prehospital ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prehospital ticagrelor treatment
Trial: 22305833
Drug: High-concentration oxygen
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration oxygen therapy (6 L/min via medium concentration mask)
Trial: 22305833
Drug: Titrated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oxygen therapy (to achieve oxygen saturation 93%-96%)
Trial: 18515518
Drug: One E2
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One E2 spray (1.53 mg E2, 90 microliter)
Trial: 18515518
Drug: Two E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two E2 sprays (3.06 mg E2, 180 microliter)
Trial: 18515518
Drug: Three E2
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three E2 sprays (4.59 mg E2, 270 microliter)
Trial: 9704785
Drug: 140 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg/dL cutoff value in oral glucose challenge test
Trial: 9704785
Drug: 142 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 142 mg/dL cutoff value in oral glucose challenge test
Trial: 9704785
Drug: 141 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 141 mg/dL cutoff value in oral glucose challenge test
Trial: 9704785
Drug: 136 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 136 mg/dL cutoff value in oral glucose challenge test
Trial: 8527690
Drug: HI-6 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HI-6 (500 mg) with atropine sulphate (2 mg)
Trial: 1978503
Drug: D-phenylalanine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-phenylalanine (0.5 grams three times the day before treatment)
Trial: 631733
Drug: Phenformin 50
RxNorm normalized name: phenformin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin 50 mg every 12 hours for 3 days before and during the fasts
Trial: 31506859
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy for Posttraumatic Stress Disorder
Trial: 30144887
Drug: Top-D (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-D (Vitamin D3 gel made from proniosomal technology) applied daily on the skin, 1 g containing 5000 IU of vitamin D3
Trial: 30144887
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel applied daily, 1 g
Trial: 24585900
Drug: Modified St.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified St. Thomas' Hospital cardioplegic solution (group S)
Trial: 24585900
Drug: Conventional glucose-insulin-potassium
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose-insulin-potassium solution (group G)
Trial: 7862844
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg alcohol
Trial: 7862844
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg alcohol
Trial: 463982
Drug: Pelvic irradiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic irradiation alone or followed by adjuvant daily chlorambucil therapy
Trial: 30283182
Drug: Lidocaine 2
RxNorm normalized name: lidocaine 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2 mg/kg/h with a maximum of 200 mg/h starting at induction of anesthesia until the end of surgery
Trial: 30283182
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg/kg iv bolus in 100ml saline over 10 min followed by infusion of 15 mg/kg/h until the end of surgery
Trial: 22517399
Drug: Cilengitide 500
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 500 mg with standard radiation and temozolomide
Trial: 22517399
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg with standard radiation and temozolomide
Trial: 22517399
Drug: Cilengitide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide (both doses) with standard radiation and temozolomide
Trial: 19751434
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy without Lactobacilli
Trial: 12409967
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion (0.625, 1.25 and 2.5 microg/kg per min for 10 min each)
Trial: 12409967
Drug: Glycyrrhetinic acid
RxNorm normalized name: Glycyrrhetinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhetinic acid (GRA; 500 mg orally 2.5 h before the study)
Trial: 9809729
Drug: Glipizide GITS
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide GITS (5 to 20 mg)
Trial: 1000519
Drug: Cis-dichlorodiammineplatinum(II) high-dose
RxNorm normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cis-dichlorodiammineplatinum(II) high-dose schedule (30 mg/m2 daily for 3 days every 4 weeks)
Trial: 1000519
Drug: Cis-dichlorodiammineplatinum(II) low-dose
RxNorm normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cis-dichlorodiammineplatinum(II) low-dose schedule (30 mg/m2 once every 2-3 weeks)
Trial: 27401882
Drug: Prolonged release
RxNorm normalized name: EYE DROPS, PROLONGED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release oxycodone/naloxone (OXN PR)
Trial: 24836758
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups (specific treatments not detailed)
Trial: 12856481
Drug: Increased digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased digoxin synthesis with upregulated tryptophan catabolism (increased serotonin, strychnine, nicotine) and downregulated tyrosine catabolism (decreased dopamine, noradrenaline, morphine) in chronic insomnia with right hemispheric dominance
Trial: 12856481
Drug: Reduced digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced digoxin synthesis with downregulated tryptophan catabolism (decreased serotonin, strychnine, nicotine) and upregulated tyrosine catabolism (increased dopamine, noradrenaline, morphine) in normal sleep patterns with left hemispheric dominance
Trial: 26943843
Drug: Transfusion threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion threshold of 10 g/dl
Trial: 26943843
Drug: Transfusion threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion threshold of 7 g/dl
Trial: 24942833
Drug: Higher NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher NT-proBNP (≥450ng/l)
Trial: 22401633
Drug: Immunoxel (Dzherelo)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunoxel (Dzherelo) administered once-daily along with TB drugs
Trial: 20590480
Drug: Bacopa monnieri
RxNorm normalized name: BACOPA MONNIERI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacopa monnieri (BacoMind(TM)) 300 mg/day
Trial: 15819764
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intrathecal morphine
Trial: 1911676
Drug: 4.0 ml
RxNorm normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 ml of 2% lignocaine containing 1:80000 adrenaline
Trial: 1911676
Drug: 4.0 ml
RxNorm normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 ml of 2% lignocaine (adrenaline-free)
Trial: 24380765
Drug: Daily Undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Undulating Periodized (DUP) training
Trial: 22324488
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg, once daily for 3 days)